The Center for Genetics and Society brings social justice and human rights to the center of public and policy discussions about human genetics and assisted reproduction.

Featured

Challenging the Legacies of Eugenics in Science, Medicine, and Technology

By CGS | 04.17.2024
Biopolitical Times

CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...

Society

Groundbreaking principles on heritable genome editing bring social justice voices to the fore

By Emily Galpern, Guest Contributor | 02.14.2024
Biopolitical Times

CGS’ Gender Justice and Disability Rights Coalition has just released Social Justice and Human Rights Principles for Global Deliberations on Heritable Genome Editing. The Principles explicitly center gender justice, disability rights, and human rights in deliberations addressing heritable genome editing, an arena that has largely been the purview of scientists and bioethicists. The Principles have been endorsed by more than 70 individuals and organizations from around the world.

Heritable genome editing – using CRISPR or other tools to alter...

Global Governance

The Unexpected Plight of Whistleblowers

By Emily Beitiks, Guest Contributor | 05.10.2024
Biopolitical Times

If you’re looking for a book where good triumphs over evil, The Occasional Human Sacrifice: Medical Experimentation and the Cost...

Arts & Culture

Gene Therapy in a Capitalist Economy

By Pete Shanks | 04.29.2024
Biopolitical Times

On April 26, Pfizer issued a press release announcing that:

U.S. FDA Approves Pfizer’s BEQVEZ™ …, a One-Time Gene Therapy...

Biopolitical Times

The Unexpected Plight of Whistleblowers

By Emily Beitiks, Guest Contributor | 05.10.2024

If you’re looking for a book where good triumphs over evil, The Occasional Human Sacrifice: Medical Experimentation and the Cost...

Arts & Culture

Gene Therapy in a Capitalist Economy

By Pete Shanks | 04.29.2024

On April 26, Pfizer issued a press release announcing that:

U.S. FDA Approves Pfizer’s BEQVEZ™ …, a One-Time Gene Therapy...

End of the Future of Humanity

By Pete Shanks | 04.25.2024

Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005...

Human Genetic Modification

News

Americans overwhelmingly say access to IVF is a good thing

By Gabriel Borelli, Pew Research Center | 05.13.2024

Photo by Campaign Creators on Unsplash

The political debate around access to in vitro fertilization (IVF) intensified this year,  following an Alabama Supreme Court decision in February that frozen embryos could be considered children.

An April Pew Research Center...

U.S. Federal

A gay couple couldn’t access IVF benefits. They’re suing New York City.

By Maham Javaid, The Washington Post | 05.09.2024

"New York City Hall" by Aude is licensed under CC BY-SA 2.5 DEED

New York City is denying in vitro fertilization benefits to thousands of gay male employees of the city and their partners, a class-action lawsuit filed...

Policies

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

By Ryan Cross, Endpoints News | 05.08.2024

A half-decade after a scientist’s reckless experiment with human embryos put a stop to much of China’s clinical work on CRISPR gene editing, local researchers are once again performing human studies of the technology.

At least three Chinese biotech companies...

Human Genetic Modification

Boy Dosed with Pfizer DMD Gene Therapy Dies a Year after Phase II Trial

By Alex Philippidis, Genetic Engineering & Biotechnology News | 05.07.2024

Pfizer has paused enrollment in a Phase III trial assessing its Duchenne muscular dystrophy (DMD) gene therapy candidate fordadistrogene movaparvovec after acknowledging the sudden death of a young boy who received the treatment last year.

The boy, whose age was...

Patents & Other IP

Video
Reproduction and Family Formation: The State and the Market
Use Gene Editing to Make Better Babies | Debate | Intelligence Squared U.S.
The 'Perfect' Baby?: The Dangers of Gene Editing in Assisted Reproduction